Ann Rehabil Med Search


Research and
publication ethics

  • HOME
  • Research and publication ethics

All manuscripts should be written with strict adherence to the “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” of International Committee of Medical Journal Editors (, updated December 2015). Issues of ethical misconduct, plagiarism, and duplicate/redundant publication will be judged and dealt with according to the “Good Publication Practice Guidelines for Medical Journals, 2nd” ( For all studies involving human subjects, the principles embodied in the Declaration of Helsinki ( should be upheld, informed consent must be obtained from all participants, and must be approved by a recognized Institutional Review Board (IRB) or research ethics committee. The editor may request submission of copies of informed consents from human subjects in clinical studies or IRB approval documents. Experiments involving animals should comply with the NIH guidelines for the use of laboratory animals ( and/or be reviewed by an appropriate committee (e.g., Institutional Animal Care and Use Committee, IACUC) to ensure the ethical treatment of animals in research. ARM will follow the guidelines by the Committee on Publication Ethics (COPE, for settlement of any misconduct.

All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the editorial board. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. There will also be penalties for the authors.
ARM follows the “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” (, updated December 2015) and the “Good Publication Practice Guidelines for Medical Journals, 2nd” ( Authorship is credited to those who have direct involvement in the study and have made significant contributions to (a) substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (b) drafting the work or revising it critically for important intellectual content; AND (c) final approval of the version to be published; AND (d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved as recommended by ICMJE. The primary investigator is designated the first author of the study, unless contested by the other authors. The corresponding author is directly responsible for communication and revision of the submitted manuscript. All persons who have made substantial contribution, but who are not eligible as authors should be named in the acknowledgments. In the case of change of authorship, a written explanation must be submitted. Change in either the first author or the corresponding author requires approval by the editorial board, and any changes in the other authors require approval by the editor-inchief.
The corresponding author of an article is asked to inform the editor of the authors’ potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest must be disclosed during the online submission process on the appropriate web page. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems based on the “ICMJE Uniform Disclosure Form for Potential Conflicts of Interest” ( The editor will decide whether the information on the conflict should be included in the published paper. Before publishing such information, the editor will consult with the corresponding author. In particular, all sources of funding for a study should be explicitly stated.
Clinical trial defined as “any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome” is recommended to be registered to the primary registry to be prior publication. ARM accepts the registration in any of the primary registries that participate in the WHO International Clinical Trials Portal (, NIH (, ISRCTN Resister (, University Hospital Medical Information Network (, Netherlands Trial Register ( or The Clinical Research Information Service ( The clinical trial registration number will be published at the end of the abstract.


Browse all articles >

Editorial Office
Department of Rehabilitation Medicine, Seoul National University Boramae Medical Center,
20 Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Korea
Tel: +82-2-870-2679    Fax: +82-2-870-2679    E-mail:                

Copyright © 2018 by Korean Academy of Rehabilitation Medicine. All rights reserved.

Developed in M2community

Close layer
prev next